Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tramadol
- Development stage
- Approved
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Rectal, Subcutaneous
01
Overview
Tramadol is a centrally acting synthetic opioid analgesic and serotonin-norepinephrine reuptake inhibitor (SNRI) used for the management of moderate to moderately severe pain in adults. It acts primarily as an agonist at the mu-opioid receptor and also inhibits the reuptake of serotonin and norepinephrine in the central nervous system. Tramadol exists as a racemic mixture with both enantiomers contributing to its analgesic effects through different mechanisms. The drug is structurally related to codeine and morphine but has about one-tenth the potency of morphine. It is available in immediate-release and extended-release formulations for oral administration. Tramadol was first approved by the FDA in 1995 for pain management[2][5][8].
- Brand names
- ConZipQdoloUltramUltram ERInvodolLarapamMabronManeoOldaramTilodolTradorecZeridameTramalDurelaRaliviaRyzoltSeglentisTriduralZytram
- Other names
- tramadol hydrochloride
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on tramadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tramadol.